PINK
IPSEY

Ipsen SA ADR

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Ipsen SA ADR Stock Price

Vitals

Today's Low:
$33.8333
Today's High:
$33.86
Open Price:
$33.86
52W Low:
$21.9562
52W High:
$33.86
Prev. Close:
$32.605
Volume:
541

Company Statistics

Market Cap.:
$10.80 billion
Book Value:
10.2898
Revenue TTM:
$3.28 billion
Operating Margin TTM:
26.54%
Gross Profit TTM:
$2.63 billion
Profit Margin:
13.7%
Return on Assets TTM:
9.39%
Return on Equity TTM:
12.52%

Company Profile

Ipsen SA ADR had its IPO on under the ticker symbol IPSEY.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Ipsen SA ADR has a staff strength of 5,300 employees.

Stock update

Shares of Ipsen SA ADR opened at $33.86 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $33.83 - $33.86, and closed at $33.83.

This is a +3.77% increase from the previous day's closing price.

A total volume of 541 shares were traded at the close of the day’s session.

In the last one week, shares of Ipsen SA ADR have increased by +6.28%.

Ipsen SA ADR's Key Ratios

Ipsen SA ADR has a market cap of $10.80 billion, indicating a price to book ratio of 2.7317 and a price to sales ratio of 2.7217.

In the last 12-months Ipsen SA ADR’s revenue was $3.28 billion with a gross profit of $2.63 billion and an EBITDA of $1.06 billion. The EBITDA ratio measures Ipsen SA ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ipsen SA ADR’s operating margin was 26.54% while its return on assets stood at 9.39% with a return of equity of 12.52%.

In Q2, Ipsen SA ADR’s quarterly earnings growth was a negative -50.4% while revenue growth was a positive 8.4%.

Ipsen SA ADR’s PE and PEG Ratio

Forward PE
11.534
Trailing PE
24.8893
PEG
0

Its diluted EPS in the last 12-months stands at $1.31 per share while it has a forward price to earnings multiple of 11.534 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ipsen SA ADR’s profitability.

Ipsen SA ADR stock is trading at a EV to sales ratio of 2.588 and a EV to EBITDA ratio of 7.0778. Its price to sales ratio in the trailing 12-months stood at 2.7217.

Ipsen SA ADR stock pays annual dividends of $1.2 per share, indicating a yield of 0.98% and a payout ratio of 23.39%.

Balance sheet and cash flow metrics

Total Assets
$6.09 billion
Total Liabilities
$1.71 billion
Operating Cash Flow
$-89300000.00
Capital Expenditure
$24.10 million
Dividend Payout Ratio
23.39%

Ipsen SA ADR ended 2024 with $6.09 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.09 billion while shareholder equity stood at $3.40 billion.

Ipsen SA ADR ended 2024 with $0 in deferred long-term liabilities, $1.71 billion in other current liabilities, 83800000.00 in common stock, $195.20 million in retained earnings and $681.00 million in goodwill. Its cash balance stood at $413.40 million and cash and short-term investments were $438.10 million. The company’s total short-term debt was $1,200,000 while long-term debt stood at $0.

Ipsen SA ADR’s total current assets stands at $1.76 billion while long-term investments were $0 and short-term investments were $24.70 million. Its net receivables were $685.60 million compared to accounts payable of $746.60 million and inventory worth $350.00 million.

In 2024, Ipsen SA ADR's operating cash flow was $-89300000.00 while its capital expenditure stood at $24.10 million.

Comparatively, Ipsen SA ADR paid $0.23 in dividends in 2024.

Other key metrics

Current Trading Price
$33.83
52-Week High
$33.86
52-Week Low
$21.9562
Analyst Target Price
$

Ipsen SA ADR stock is currently trading at $33.83 per share. It touched a 52-week high of $33.86 and a 52-week low of $33.86. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $31.4 and 200-day moving average was $29.05 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0.9% are held by institutions.

Frequently Asked Questions About Ipsen SA ADR

The stock symbol (also called stock or share ticker) of Ipsen SA ADR is IPSEY

The IPO of Ipsen SA ADR took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$8.36
0.36
+4.5%
$494.9
-27.7
-5.3%
$83.04
-4.37
-5%
$199
-11.4
-5.42%
Amgen Inc (AMGN)
$260.31
-1.41
-0.54%
Transcat Inc (TRNS)
$111.94
-0.11
-0.1%
$212.5
0.5
+0.24%
$138
-6.9
-4.76%
INDO AMINES LTD.-$ (INDOAMIN)
$121.15
-13
-9.69%
$111.46
2.58
+2.37%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Address

65 Quai Georges Gorse, Boulogne-Billancourt, France, 92100